share_log

BTIG Maintains Buy on Exagen, Lowers Price Target to $5

Benzinga ·  Mar 22, 2023 08:17

BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $6 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment